Column: Focus on Biopharmaceutical Analysis

Dec 01, 2017
LCGC North America
Several key applications of biolayer interferometry in pharmaceutical development have emerged recently. Here, we evaluate its use for easuring product titer from fermentation, and compare the strengths and weaknesses of the technique to those of HPLC.
Jun 01, 2017
LCGC North America
Significant recent advances now enable routine usage of HDX-MS for comparing the conformations of biopharmaceutical products.
Jan 01, 2017
LCGC North America
What are the best methodologies for demonstrating comparability?
Sep 01, 2016
LCGC North America
For testing various attributes of proteins, CE–MS is superior to LC–MS. And despite common fears, it is a robust tool. But adapting an LC–MS method to CE–MS requires careful optimization.
Jul 01, 2016
LCGC North America
In this column, we introduce the basics of today’s approaches for doing intact protein dissociation with mass spectrometry (MS), or top-down sequencing (that is, rather than the more conventional peptide-based “bottom-up” sequencing where future improvements might occur, advantages and limitations of using top-down sequencing, possible applications, and why it has become such an important and pursued research area for many.
Jan 01, 2016
LCGC North America
Best practices and recent advances in characterizing glycosylation
Sep 01, 2015
LCGC North America
A sigmoidal gradient can significantly reduce the time of analysis, while retaining selectivity and resolution.
Jul 01, 2015
LCGC North America
An overview of best practices for assessing protein aggregation, including the importance of using a multimethod approach
Jan 01, 2015
LCGC North America
Most analytical approaches used for the determination of low-molecular-weight noncovalent aggregates in protein pharmaceuticals suffer from important limitations. This first part of this two-part column series discusses those limitations.
Dec 01, 2014
LCGC North America
In this installment, we discuss fluorescence-detection size exclusion chromatography (FSEC) technology and its implications in protein characterization, specifically the development and characterization of biologics.
lorem ipsum